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Abstract
Background: Self-inactivating retroviral vectors (SIN) are often associated with very low titers.
Promoter elements embedded within SIN designs may suppress transcription of packageable
retroviral RNA which in turn results in titer reduction. We tested whether this dominant-negative
effect involves histone acetylation state. We designed an MLV-derived SIN vector using the
cytomegalovirus immediate early enhancer-promoter (CMVIE) as an embedded internal promoter
(SINCMV) and transfected the pantropic 293GPG packaging cell line.
Results: The SINCMV retroviral producer had uniformly very low titers (~10,000 infectious
retroparticles per ml). Northern blot showed low levels of expression of retroviral mRNA in
producer cells in particular that of packageable RNA transcript. Treatment of the producers with
the histone deacetylase (HDAC) inhibitors sodium butyrate and trichostatin A reversed
transcriptional suppression and resulted in an average 106.3 ± 4.6 – fold (P = 0.002) and 15.5 ± 1.3
– fold increase in titer (P = 0.008), respectively. A histone gel assay confirmed increased histone
acetylation in treated producer cells.
Conclusion: These results show that SIN retrovectors incorporating strong internal promoters
such as CMVIE, are susceptible to transcriptional silencing and that treatment of the producer cells
with HDAC inhibitors can overcome this blockade suggesting that histone deacetylation is
implicated in the mechanism of transcriptional suppression.
Background
Retroviral vectors derived from C-type mammalian retro-
viruses are characterized by their ability to integrate into
the chromosomal DNA of their target cells. For this rea-
son, they have been a favored method of gene transfer
into dividing cells in approaches where stable and sus-
tained gene expression is desired or necessary. Conven-
tional retroviral vectors resemble in their architecture their
wild-type counterparts in that they retain cis-acting pro-
moter sequences located in the 5' and the 3' long terminal
repeats (LTRs) and the Ψ signal that allows the packaging
of recombinant RNA into viral particles [1,2].
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Many retroviral vectors employ the use of inducible or tis-
sue-specific promoters that are incorporated into the vec-
tor design to allow for regulated or targeted gene
expression. However, the transcriptional activity of an
embedded promoter can be compromised by interfer-
ences from the strong enhancer and promoter machinery
in the flanking retroviral LTRs [3-5]. To bypass this prob-
lem, self-inactivating retroviral vectors (SIN) have been
designed whereby the viral enhancer and/or promoter
sequences are deleted from the U3 region of the 3'LTR.
Following reverse transcription in transduced cells, the 3'
LTR deletions will be copied to the 5'LTR by template
switch rendering the vector transcriptionally inactive [6-
8].
SIN vectors have been successfully used to drive regulated
transgene expression by inducible promoters [9,10] and
to confer restricted gene expression by cell type-or tissue-
specific promoters [11-15]. Additionally, the SIN configu-
ration results in relatively safer vectors for human gene
therapy applications by reducing the risk of aberrant acti-
vation of cellular oncogenes adjacent to the integrated
provirus site and by minimizing the risk of production of
replication competent retroviruses (RCRs) [3,16]. For
these reasons, SIN vectors have beenused in many cell and
gene therapy applications including vectors derived from
murine leukemia virus (MLV) [17-19], and lentivirus
[20,21]. Despite their desired features, SIN vectors possess
a number of limitations. They can be genetically unstable
[22,23] and may exhibit rescue of the U3-deletion in the
3' LTR by the intact 5'LTR due to recombination events
[6,24]. To prevent such reconstitution events, hybrid
5'LTRs have been used in which the U3 is replaced by non-
homologous enhancer or promoter sequences such as the
cytomegalovirus (CMV) enhancer-promoter [25,26].
Moreover, SIN vectors are often associated with reduced
titers which greatly limit their gene transfer efficiency
[27,28]. As is the case for conventional retroviral vectors,
low titers from SIN retrovectors could in part be due to
transcriptional suppression of the expression of the neces-
sary trans-components in packaging cells that are required
for the production of the retroviral particles. Low titers
from certain MLV-based SIN vectors have been also attrib-
uted to inefficient polyadenylation of the viral RNA due to
extensive deletions made to the U3 region of the 3'LTR.
Such deletions included the TATA box affecting the nearby
R region which is implicated in polyadenylation [8,29].
We propose that interferences between elements of strong
promoters incorporated within SIN retroviral vector
designs and sequences in the 5'LTR can lead to suppres-
sion of retroviral RNA transcription which in turn results
in reduction of SIN retrovector titers. We hypothesize that
the mechanism of transcriptional suppression in SIN vec-
tors involves the recruitment of histone deacetylases
(HDACs). To test this, we designed a SIN retroviral vector
whereby a deletion was made to the U3 region of Molo-
ney murine leukemia virus (Mo-MLV) 3'LTR removing
most of the enhancer machinery that is intrinsic to the ret-
rovirus. In this SIN template, a CMV promoter replaces
the U3 region in the 5'LTR and drives expression of the
retrovector mRNA in transfected packaging cell lines. As
an internal promoter, we used the CMV immediate early
enhancer-promoter (CMVIE) to drive expression of the
enhanced green fluorescent protein (EGFP) reporter in
transduced cells. The CMVIE is a very potent promoter
and has been typically incorporated into retroviral and
lentiviral backbones to drive strong transgene expression
[21,26].
Here, we show that transcription of retroviral RNA from
the resultant SINCMV retrovector was suppressed in trans-
fected 293GPG producer cells that had dramatically low
titers (~104 viral particles per ml). We further demonstrate
that treatment of the SINCMV retroviral producers with
the HDAC inhibitors sodium butyrate and Trichostatin A
(TsA) reversed the transcriptional suppression and
resulted in a significant increase in the SIN retroviral titer.
Results
SINCMV retrovector design and increased retroviral RNA 
transcription with sodium butyrate treatment in 
transfected 293GPG producer cells
A SIN vector was derived from a Mo-MLV-based vector,
pLTRGFP, by creating a 311-bp NheI-SacI deletion to the
3'LTR, thus removing all the retroviral enhancers and the
CAAT box (Figure 1A). Then, the SINCMV vector was
made by incorporating the CMVIE enhancer-promoter
into the construct upstream of the cDNA for EGFP
reporter to drive strong transgene expression in trans-
duced cells (Figure 1B). In this design, the CMV promoter
in the hybrid 5'LTR drives the expression of a full-length
2.6 kb RNA transcript that can be packaged into retropar-
ticles and a ~2.1 kb spliced form that lacks the packaging
signal (Ψ). The internal CMVIE drives the expression of a
shorter ~1 kb transcript. Hence, retroviral RNA transcrip-
tion from SINCMV proviral DNA in transfected producer
cells should hypothetically result in 3 RNA transcripts, but
only one is packageable (Figure 1B).
We then generated SINCMV retroviral producers by stable
transfection of the 293GPG packaging cell line. The result-
ant polyclonal as well as isolated single clone producer
populations were utilized to generate VSV-G pseudotyped
retroviral particles and had very low titers in the range of
~104 viral particles per ml (see below). To test if strong
promoter sequences incorporated within the SIN design
can lead to suppression of retroviral RNA transcription
which in turn results in reduction of SIN retrovector titers,
total RNA was extracted from stable 293GPG-SINCMVVirology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
Page 3 of 12
(page number not for citation purposes)
SINCMV vector design and transcript expression in retroviral producer cells Figure 1
SINCMV vector design and transcript expression in retroviral producer cells. A. The control SIN vector lacking an 
internal promoter has major deletions in the 3'LTR enhancer elements rendering its intrinsic promoter machinery transcrip-
tionally inactive in transduced cells. B. Transgene expression in the SINCMV design is driven by the internal CMVIE promoter 
embedded upstream of the reporter EGFP. Three RNA transcripts are expected from SINCMV proviral DNA transcription in 
transfected packaging cells. The upstream CMV promoter in the 5'LTR drives the expression of a full-length ~2.6 kb transcript 
that can be packaged into retroparticles and a ~2.1 kb spliced form that lacks the packaging signal (Ψ). The internal CMVIE 
drives the expression of a shorter ~1 kb transcript. C. Hybridization with a P32- labelled EGFP probe done on total RNA 
extracted from SINCMV retroviral producers treated with butyrate indicated significant increase in the level of retrovector 
mRNA. D. Loading control of the 3 RNA samples is shown by ribosomal RNA staining with ethidium bromide.
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producer cells, loaded onto an RNA gel, and Northern
Blot analysis for the SINCMV retrovector mRNA was done
using a P32-labeled GFP probe (Figure 1C). Expression of
the 3 predicted retroviral RNA transcripts in these cells
was very low with almost undetectable levels of the full-
length packageable transcript from the upstream CMV
promoter. However, treatment of the producer cells with
10 mM and 20 mM sodium butyrate for 48 hr resulted in
a significant increase in the expression of the three tran-
scripts and of particular importance of the non-spliced
SINCMV retrovector mRNA which was undetectable in
the untreated control cells. Loading of the 3 samples was
controlled for by ribosomal RNA as shown by ethidium
bromide imaging (Figure 1D).
Increase in titer of SINCMV producers with sodium 
butyrate treatment and enhanced gene transfer into A549 
cells with improved SINCMV viral titers
To determine if increased retroviral RNA transcription
with sodium butyrate treatment, in particular that of the
packageable retrovector transcript, would result in
improved viral titer, SINCMV retroviral producers were
treated with increasing doses of sodium butyrate for 48 hr,
after which viral supernatants were harvested in fresh
media. Following transduction of A549 cells, viral titer
was measured as infectious viral particles per ml. Interest-
ingly, 10 mM butyrate treatment resulted in a significant
42.1 ± 1.4-fold increase in viral titer (P = 0.001) as com-
pared to that of control untreated producers (Figure 2B).
Moreover, the increase in SINCMV retroviral titer was
dose-dependent. A maximal 106.3 ± 4.6-fold increase in
titer was obtained with 20 mM sodium butyrate treatment
(P = 0.002) as determined from three independent exper-
iments. By contrast, similar butyrate treatment of the pro-
ducer cells for the control vector lacking the internal
CMVIE promoter (Figure 2A) which had an average titer
of ~ 5 × 105 viral particles per ml resulted in only a modest
3.2 ± 0.9-fold increase with 10 mM butyrate (P = 0.136)
and 1.6 ± 0.4-fold increase with 20 mM butyrate (P =
0.299). Note that the upfront titer of the control SIN vec-
tor prior to butyrate treatment was 50-fold higher than
that of the SINCMV vector.
A549 lung carcinoma cells, plated in 6-well dishes at the
same number, were transduced with an equal sample vol-
ume of SINCMV retroviral supernatants collected from
control untreated producers (Figure 2C, a) as well as from
producers treated with 10 mM butyrate (Figure 2C, b) and
20 mM butyrate (Figure 2C, c). Flow cytometry analysis of
green fluorescence on gene modified cells revealed a strik-
ing increase in gene transfer efficiency into target cells
using SINCMV retroviral supernatants from 10 mM and
20 mM butyrate treated producers whereby 68% and 97%
of the target cells were positive for the EGFP reporter
respectively. On the other hand, only 4.5% of A549 cells
were transduced with an equal volume of the control
supernatant from untreated producer.
Increased histone acetylation in SINCMV producer cells 
treated with sodium butyrate
To confirm that sodium butyrate treatment resulted in
increased histone acetylation in SINCMV producer cells,
histone proteins were isolated from control untreated
producers as well as cells treated with increasing doses of
sodium butyrate. The samples were then analyzed for
their acetylation status using an Acid Urea Triton gel elec-
trophoresis (Figure 3) that separates histone proteins
based on charge density in addition to size and shape,
hence allowing for the detection of posttranslational
modifications such as acetylation. In such a gel, the addi-
tion of an acetyl group to a lysine residue on a histone
protein renders the modified protein less positive and
therefore it slows down its migration in the gel. Using His-
tone 4 as an indicator, we observed increased acetylation
of histone proteins from SINCMV producer cells that were
treated with 10 mM sodium butyrate as compared to con-
trol, untreated producers. This increase in histone acetyla-
tion was even more evident in samples treated with 20
mM butyrate as can be clearly seen from the shift to
greater levels of tri-acetylated and the appearance of tetra-
acetylated (Ac4) histone H4 as the dose of sodium
butyrate increases.
Increase in titer of SINCMV producers with Trichostatin A 
treatment
To determine if the resultant increase in SINCMV retrovi-
ral titers with sodium butyrate treatment is specifically
due to inhibition of histone deacetylation rather than a
non-specific transcriptional upregulation effect, Trichos-
tatin A which is a potent and specific inhibitor of histone
deacetylation was assessed for its effect on SINCMV retro-
viral titer. Treatment of the producer cells with ≤ 1 µM TsA
for 48 hr did not result in any significant increase in retro-
viral titer (Figure 4A). However, using higher drug concen-
trations, an average 15.5 ± 1.3-fold increase in titer was
obtained with 3 µM TsA treatment compared to control (P
= 0.008).
Discussion
Self-inactivating retroviral vectors are frequently designed
with strong internal promoters to drive transgene expres-
sion in transduced cells, yet these designs are often associ-
ated with poor retrovector production. Low titers in the
range of 104 – 105 colony-forming units per ml (cfu/ml)
have been reported from SIN retrovectors that incorpo-
rated the SV40 promoter or the mouse metallothionein I
(MT) promoter [6]. A dramatically low titer of ~103cfu/ml
was obtained from a SIN retrovector which had the TK
promoter in sense orientation and the hMT inducible pro-
moter in antisense orientation. In another study, a SINVirology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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Titer of SINCMV retroviral producers treated with sodium butyrate and transduction of A549 cells with retrovirus from  butyrate treated SINCMV producer cells Figure 2
Titer of SINCMV retroviral producers treated with sodium butyrate and transduction of A549 cells with retro-
virus from butyrate treated SINCMV producer cells. A. Treatment of control retroviral producer cells with the histone 
deacetylase inhibitor sodium butyrate for 48 hr resulted in a modest 1.6 ± 0.4-fold increase in titer (P = 0.299). B. Treatment of 
SINCMV retroviral producer cells with sodium butyrate for 48 hr resulted in a maximal 106.3 ± 4.6-fold increase in titer (P = 
0.002) that was obtained with 20 mM butyrate. C. A549 lung carcinoma cells were transduced with same volume of retroviral 
supernatant that was collected from control-untreated SINCMV producers (a), producers treated with 10 mM sodium 
butyrate (b), and 20 mM sodium butyrate (c). % EGFP positive cells for each sample and mean EGFP reporter expression in the 
gated population (MnX) indicate a marked increase in gene transfer into target cells with supernatant from butyrate treated 
producers.
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Histone gel assay on SINCMV producer cells treated with sodium butyrate Figure 3
Histone gel assay on SINCMV producer cells treated with sodium butyrate. Treatment of SINCMV retroviral pro-
ducer cells with increasing doses of sodium butyrate for 48 hr resulted in increased histone acetylation as most obvious with 
histone H4.Virology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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Titer of SINCMV retroviral producers treated with TsA and model depicting mechanism of transcriptional suppression in the  SINCMV design Figure 4
Titer of SINCMV retroviral producers treated with TsA and model depicting mechanism of transcriptional 
suppression in the SINCMV design. A. Treatment of SINCMV retroviral producer cells with the histone deacetylase inhib-
itor TsA for 48 hr resulted in a maximal 15.5 ± 1.3-fold increase in titer (P = 0.008) that was obtained with 3 µM TsA. B. Inter-
ferences between strong elements in the internal CMVIE enhancer-promoter and the upstream CMV promoter in the 5'LTR 
lead to the recruitment of histone deacetylases (HDACs) which trigger an inactive chromatin conformation at the promoter 
sites leading to transcriptional suppression of the retroviral RNA.Virology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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design with an internal hybrid promoter composed of the
human beta-globin promoter and CMV enhancer
sequences resulted in poor gene transfer efficiency likely
due to lowered titers [27]. Moreover, Mo-MLV based ret-
roviral vectors with hybrid LTRs incorporating large por-
tions of the melanoma-specific murine tyrosinase
enhancer/promoter also had titers in the range of 103cfu/
ml [28]. A later study reported very low viral titers of
103cfu/ml for SIN vectors in which the Mo-MLV enhanc-
ers were swapped by tandem repeats of the core element
of the tyrosinase enhancer and the Mo-MLV promoter was
substituted with the stronger SV40 promoter in an
attempt to generate targeted retroviral vectors with higher
levels of expression [30]. The authors attributed reduced
titers in the latter studies to decreased efficiency of reverse
transcription due to loss of a small part of the R region in
the LTR. Their results also suggested a negative interfer-
ence of the tyrosinase enhancer on the viral enhancer
when the latter was retained in the 3'LTR. It has been also
reported that the muscle creatinine kinase enhancer had a
partial suppressive effect over the viral enhancer in the
LTR [31]. Based on these findings, we speculated that
interferences between elements of strong promoters
incorporated within SIN designs and sequences in the
5'LTR can lead to suppression of retroviral RNA transcrip-
tion which in turn results in reduction of titers from these
vectors.
To assess the effect of promoter interferences within SIN
retrovectors on viral RNA transcription and titer, we
designed a Mo-MLV-based SIN vector by removing all the
enhancers and the CAAT box from the 3'U3 region (Figure
1A). The TATA box and the R region were left intact to
ensure efficient polyadenylation. Then, as an internal pro-
moter, we incorporated the CMVIE enhancer promoter
which is among the most potent enhancer-promoters
known and has been typically incorporated into retroviral
and lentiviral backbones to drive strong transgene expres-
sion [32,33]. The resultant SINCMV design (Figure 1B)
which had low titers in the range of ~104 viral particles per
ml has a hybrid 5'LTR in which a CMV promoter replaces
the U3 region to ensure strong expression in transfected
packaging cells and to minimize the risk of rescue of the
SIN deletion in the 3'LTR. We expected interferences
between the internal CMVIE and the upstream 5'CMV in
the SIN retrovector configuration as competitive inhibi-
tion between the two promoters was previously reported
in plasmid constructs [34]. Indeed, very low levels of ret-
roviral RNA transcripts derived from both promoters were
obtained in producer cells transfected with SINCMV vec-
tor (Figure 1C). The expression of the full-length package-
able transcript by the 5'CMV promoter was almost
completely abrogated indicating a stronger interference
from the internal CMVIE. Moreover, in the absence of
butyrate, we observed 50-fold higher retroviral titers in a
SIN vector identical in all aspects to the SINCMV design
except for the absence of the internal CMVIE promoter
(Figure 2A). The sum of these observations strongly sup-
ports the notion that CMVIE is a potent cis-acting suppres-
sor of promoters 5' to its location within a plasmid vector
construct.
In recent years, there has been growing evidence that
interference between promoter sequences are mediated by
modifications to histone proteins which structurally and
functionally interact with DNA. Such modifications result
in modulation of chromatin conformation around a pro-
moter site leading to transcriptional activation or suppres-
sion. In a previous study, results from P1 nuclease analysis
strongly suggested that the CMVIE and the CMV
sequences compete for the formation of active chromatin
[34]. Additionally, other studies provided biochemical
evidence that acetylation of histone proteins by histone
acetyl transferases (HATs) at specific lysine residues on the
amino-terminal tail domains results in active chromatin
conformation [35,36]. Moreover, recent evidence linking
several transcription factors such as Gcn5, CBP/p300, and
TAFII250 to HAT activity strongly suggests a role for
acetylation in transcriptional activation. On the other
hand, deacetylation of histone proteins at a promoter site
by histone deacetylases (HDACs) has been associated
with transcriptional suppression. The mechanism is not
well understood but several models have been proposed
including disruption of the transcription initiation com-
plex, or simply preventing its assembly, or changes in the
higher-order structure of chromatin rendering it incom-
patible with transcription [37].
In fact, HDAC inhibitors have long been used as transcrip-
tional activators. Butyrate, the first identified HDAC
inhibitor [38], was used to induce gene expression from
type C virus [39] and HIV LTR [40] in infected mamma-
lian cells. However, at the time, it was not known by
which mechanism butyrate treatment enhanced LTR-
driven gene expression. More recent work demonstrated
that HDAC inhibitors can activate transcription from inte-
grated viral promoters [41,42]. Thus, we exploited the use
of sodium butyrate for reactivation of retroviral RNA tran-
scription in the SINCMV design. Our results show that
treatment of the SINCMV producer cells with 10 mM and
20 mM sodium butyrate for 48 hr resulted in a significant
increase in the expression of the three viral RNA tran-
scripts (Figure 1C). Of particular importance is the non-
spliced packageable retrovector mRNA that is derived
from the upstream 5'CMV promoter that was undetecta-
ble in the untreated control cells. Since the level of expres-
sion of packageable transcript is rate limiting for viral
production, low levels of retroviral transcript expression
in untreated producers could have contributed to the
reduced viral titer obtained initially. Interestingly, treat-Virology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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ment of the SINCMV retroviral producers with increasing
doses of sodium butyrate not only reversed transcrip-
tional suppression in the vector, but it also resulted in a
significant increase in viral titer (Figure 2B). The effect was
dose dependen. Improved titers resulted in a strikingly
enhanced gene transfer into A549 lung carcinoma cells
(Figure 2C). Furthermore, a histone gel assay confirmed
increased histone acetylation in SINCMV producer cells
treated with sodium butyrate (Figure 3).
HDAC inhibitors were used in previous studies to boost
up production from conventional (non-SIN) retroviral
[43-45] and lentiviral [46] vectors. In one study, produc-
tion of a retroviral vector expressing the normal human
cystic fibrosis transmembrane conductance regulator
(CFTR) cDNA was significantly enhanced by sodium
butyrate treatment of the producer cells with a simultane-
ous increase in the steady-state levels of LTR-driven full-
length retrovector RNA [43]. The authors suggested that
the cDNA of CFTR caused an "ill-defined" interference
with the LTR transcriptional activity that could have
resulted in upfront low titers. However, it is worth noting
that their retroviral vector had an internal simian virus40
(SV40) promoter upstream of the neomycin selectable
marker. Therefore, it is possible that the low titers associ-
ated with this vector could have also resulted from an
interference effect between the internal SV40 promoter
and the 5'LTR. Moreover, the viral supernatant was har-
vested from butyrate-containing media that could have
lead to increased transgene expression from the integrated
viral promoter in transduced cells. Therefore, not all the
increase in expression in transduced cells could be attrib-
uted to an increase in viral titer and gene transfer.
Since histone hyperacetylation resulting from HDAC inhi-
bition is only one of many cellular changes triggered by
sodium butyrate treatment [38], TsA which is a highly spe-
cific and more potent HDAC inhibitor [47] was used to
determine if histone acetylation is specifically involved in
enhanced SINCMV titers. Our results show that treatment
of the SINCMV retroviral producer cells with 3 µM TsA
resulted in a significant increase in titer indicating that
histone deacetylation is indeed implicated in suppression
of retroviral RNA transcription in the SINCMV design
resulting in reduced titers (Figure 4A). Hereby, we pro-
pose a model depicting mechanism of transcriptional sup-
pression in the SINCMV design. It is likely that
interferences between strong elements in the internal
CMVIE enhancer-promoter and the upstream promoter
elements in the 5'LTR lead to the recruitment of histone
deacetylases (HDACs) that triggers an inactive chromatin
conformation at the promoter sites leading to transcrip-
tional suppression of the retroviral RNA (Figure 4B).
However, since the improvement in SINCMV titer with
TsA treatment was less marked than that with butyrate,
this is highly suggestive that other mechanisms are likely
involved.
Conclusion
In conclusion, our results suggest that SIN retrovectors
incorporating strong internal promoters are susceptible to
significant transcriptional silencing in packaging cells
leading to poor retroviral titers. Treatment of the producer
cells with HDAC inhibitors can overcome this blockade
suggesting that histone deacetylation is implicated in the
mechanism of transcriptional suppression. These findings
give us insights for improvement of SIN vector designs
with important implications on SIN vector production in
many cell and gene therapy applications.
Methods
Cell lines and plasmids
pJ6ΩBleo plasmid and 293GPG retroviral packaging cell
line [48] were generous gifts from Richard C. Mulligan
(Children's Hospital, Boston, MA, USA). 293GPG cells
were maintained in 293GPG media [DMEM (Gibco-BRL,
Gaithesburg, MD), 10%heat-inactivated FBS (Gibco-BRL)
supplemented with 0.3 mg/ml G418 (Mediatech, Hern-
don, VA), 2 µg/ml puromycin (Sigma, Oakville, ONT),
and 1 µg/ml tetracycline (Fisher Scientific, Nepean,
ONT)]. A549, a human lung carcinoma cell line, was
obtained from the American Type Culture Collection
(ATCC, Manassas, VA) and was maintained in DMEM
supplemented with 10%heat-inactivated FBS and 1%
penicillin-streptomycin.
SINCMV retrovector design and synthesis
We used a derivative of pLTRGFP [10] to generate the SIN-
CMV design. pLTRGFP contains the cDNA for the
enhanced green fluorescent protein (EGFP) reporter and a
full-length LTR whose U3 region is derived from MSCV
and whose R and U5 regions are derived from pCMMPLZ,
a MFG derivative. We derived a self-inactivating vector
from pLTRGFP by creating a 311-bp NheI-SacI deletion to
the 3'LTR to remove all the enhancers and the CAAT box.
The synthesis of SINCMV was as follows. The 655-bp
insert encoding for the CMVIE enhancer-promoter was
excised by AseI/Klenow and AgeI digest of a shuttle vector
that was derived from pEGFP-C1 (CLONTECH, Palo Alto,
CA). This insert was ligated into the product of BglII/Kle-
now and AgeI digest of the NheI-SacI SIN-derivative in
order to generate the SINCMV plasmid. Both control SIN
and SINCMV vectors incorporate the CMV promoter in
the 5'LTR that drives expression in transfected producer
cells. Nucleotide sequences of the mutated 3'LTR and the
inserted CMVIE promoter were confirmed by DNA
sequencing (GenAlyTic Inc., University of Guelph, ONT).Virology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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Generation of the retroviral producers
The retroviral producers were generated by stable transfec-
tion of the 293GPG packaging cell line as previously
described [10]. In brief, stable producer cells were gener-
ated by co-transfection of 5 µg FspI-linearized control SIN
vector or SINCMV vector and pJ6ΩBleo plasmid at a 10:1
ratio. Transfected packaging cells were subsequently
selected in 293GPG media supplemented with 100 µg/ml
Zeocin (Invitrogen, San Diego, CA) for 3-to-4 weeks.
Resulting stable polyclonal as well as isolated single clone
producer populations were utilized to generate VSV-G
pseudotyped retroviral particles. We selected producer
clone 4 to perform subsequent experiments with butyrate.
TsA experiments were performed on the polyclonal pro-
ducer population to rule out any clonal effect that may
have attributed to increased titers from producer clone 4
with butyrate treatment.
Treatment of producers with histone deacetylase 
inhibitors for retroviral production
Working stocks of 1 M sodium butyrate were prepared
from concentrated n-Butyric Acid (Acros Organics, NJ) in
distilled water, then filtered with 0.2-micron syringe
mounted filters (Gelman Sciences, Ann Arbour, MI), and
stored at 4°C. Trichostatin A (TsA) stock (BIOMOL
Research Laboratories, Inc., PA) was stored at -20°C. The
treatment of control SIN or SINCMV producer cells with
histone deacetylase inhibitors was as follows. The retrovi-
ral producer cells were maintained in 293GPG media in
100-mm tissue culture dishes. At 70 to 80% confluency,
the tetracycline-containing media was replaced with com-
plete DMEM to allow for VSV-G expression and subse-
quently for retroviral production. One day post
tetracycline withdrawal, either sodium butyrate in mM or
TsA in µM concentrations were added to the cells in com-
plete DMEM media for 48 hr, at 37°C and 5%CO2. After-
wards, the drug-containing supernatant was discarded
and fresh complete DMEM media was added to the pro-
ducer cells to harvest retroviral supernatant in 24 hr. All
viral supernatants were filtered with 0.45-micron syringe
mounted filters (Gelman Sciences) and stored at -20°C.
Viral titer determination and RCR assay
A549 target cells were plated in 6-well dishes at 4 × 104
cells per well and allowed to adhere overnight in complete
media (DMEM, 10%heat inactivated FBS, and 50 units/ml
Pen/Strep) at 37°C and 5%CO2. The following day, the
overlaying medium was aspirated and replaced with 1 ml
per well of serial dilutions in complete DMEM media of
the viral sample supplemented with 6 µg/ml Polybrene
(Sigma). Target cells were then incubated with the viral
dilutions overnight at 37°C and 5%CO2. Subsequently,
they were washed with 2 ml per well of phosphate-buff-
ered saline and were then expanded in culture in complete
DMEM media. Flow cytometry analysis (FACStar sorter,
Becton Dickinson, Mountain View, CA) was then per-
formed on these samples within 5-to-10 days following
transduction to ascertain retrovector expression and gene
transfer efficiency as measured by EGFP fluorescence. The
viral titer was calculated from the gene transfer values
obtained with each viral dilution and expressed as infec-
tious particles per ml. Viral preparations were devoid of
replication competent retrovirus (RCR) as determined by
the standard EGFP marker rescue assay performed on null
A549 cells with conditioned supernatant collected from
transduced A549 cells.
RNA extraction from SINCMV retroviral producer cells
Total RNA was extracted from stable 293GPG-SINCMV
retroviral producer cells using TRIZOL reagent (Gibco-
BRL, Gaithersburg, MD) according to the manufacturer's
specifications. In brief, cells from 90% confluent 10-cm
tissue culture dish were lysed with 1 ml of the TRIZOL
solution. RNA was then extracted with 100% chloroform
and precipitated with 100% isopropanol at -80°C for over
1 hr. The precipitated RNA was then washed with 75%
ethanol, air-dried for 5 min and resuspended in diethylpy-
rocarbonate (DEPC)-treated water and stored at -80°C.
Northern blot assay
Samples of 10 µg total RNA in loading buffer were heated
at 60°C for 10 min, then loaded onto a 1% agarose-1.1%
formaldehyde gel, and electrophoresed in 1X MOPS
buffer for 3 hr at 150V. Afterwards, the gel was photo-
graphed under UV exposure and the RNA was transferred
overnight onto a Hybond™-N nylon membrane opti-
mized for nucleic acid transfer (Amersham Pharmacia
Biotech, Buckinghamshire, England) using 20X SSC trans-
fer buffer. The blotted RNA was then UV cross-linked to
the membrane and hybridized at 68°C using the
ExpressHyb™ Hybridization Solution (Clontech, Palo
Alto, CA) with a P32 labeled EGFP probe prepared by the
random oligolabelling kit (Amersham Pharmacia Biotech,
Piscataway, NJ). The hybridized blot was washed twice at
68°C with 2X SSC/0.1% SDS and 0.2X SSC/0.1% SDS
respectively, then exposed to X-ray photographic film
(Kodak X-Omat) at -80°C.
Isolation of histone proteins from SINCMV retroviral 
producers
The isolation of histone proteins was done with some
modifications to a previously described procedure [49].
SINCMV retroviral producer cells were trypsinized from a
confluent 100-mm tissue culture dish, washed with PBS,
and spun at 1800 rpm for 5 min. The cell pellet was re-sus-
pended and lysed in 1 ml ice-cold Nuclear Buffer (NB)
(0.25M sucrose, 0.2M NaCl, 10 mM Tris/HCl – pH 8.0, 2
mM MgCl2, 1 mM CaCl2, and 1% Triton X-100) supple-
mented with protease inhibitors (Complete, Mini, EDTA-
free, Roche Diagnostics, Mannheim, Germany) and re-Virology Journal 2006, 3:27 http://www.virologyj.com/content/3/1/27
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spun at 13000 rpm for 1 min to pellet the nuclei. The
nuclei-containing pellet was then resuspended and incu-
bated in 100 µl of 0.2M H2SO4 at 4°C overnight. After-
wards, the insoluble fraction was pelleted at 13000 rpm
for 10 min and the supernatant containing the histone
proteins was transferred to a clean 1.5 ml tube. The Bio-
Rad Protein Assay kit (Bio-Rad Laboratories, Hercules,
CA) was used to determine the protein content in the
supernatant. Histone proteins were then precipitated
using 900 µl ice-cold acetone at -20°C overnight, and air-
dried for 5 min after spinning at 13000 rpm for 10 min.
Finally, the isolated histone proteins were re-suspended to
5 µg/µl in Acid Urea (AU) sample buffer (8M urea, 10%
glycerol, 5% acetic acid, and 2% w/v methyl green dye).
Acid Urea Triton (AUT) gel electrophoresis
Analysis of histone acetylation was performed using Acid
Urea Triton (AUT) gel electrophoresis that was done with
little modifications to procedures described previously
[49,50]. We used a gel (Mini PROTEAN II-Bio-Rad) that
consisted of 12% (w/v) acrylamide, 0.08% bisacrylamide,
5% acetic acid, 8M urea, 6 mM Triton X-100 and polym-
erized with TEMED and 25% ammonium persulfate
(APS). After polymerization, the gel was pre-run for 2 hr
in 5% acetic acid buffer at 200V. Then, fresh 5% acetic
acid was used and 30 µg of each sample was loaded onto
the gel and electrophoresed at 135V- 200V until the
bromophenol blue dye migrated out. Finally, the gel was
stained for 2 hr with 0.03% Coomassie Brilliant Blue
R250 plus 50% ethanol, and 10% acetic acid. In order to
visualize the protein bands, the gel was de-stained using
20% ethanol and 10% acetic acid.
Statistics
Unless otherwise specified, all results are reported as aver-
age of three independent experiments ± standard error of
the mean. Student T test was applied using Microsoft Excel
software.
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